Cargando…

Diagnostic accuracy of copeptin sensitivity and specificity in patients with suspected non-ST-elevation myocardial infarction with troponin I below the 99th centile at presentation

OBJECTIVE: To determine whether copeptin-us can rule out diagnosis of non-ST-segment elevation myocardial infarction (NSTEMI) without prolonged monitoring and serial blood sampling in patients with high-sensitive cardiac troponin I (hs-cTnT) below the 99th centile at presentation to the emergency de...

Descripción completa

Detalles Bibliográficos
Autores principales: Duchenne, Jonathan, Mestres, Stéphanie, Dublanchet, Nicolas, Combaret, Nicolas, Marceau, Geoffroy, Caumon, Laurent, Dutoit, Laurent, Ughetto, Sylvie, Motreff, Pascal, Sapin, Vincent, Schmidt, Jeannot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975746/
https://www.ncbi.nlm.nih.gov/pubmed/24662448
http://dx.doi.org/10.1136/bmjopen-2013-004449
Descripción
Sumario:OBJECTIVE: To determine whether copeptin-us can rule out diagnosis of non-ST-segment elevation myocardial infarction (NSTEMI) without prolonged monitoring and serial blood sampling in patients with high-sensitive cardiac troponin I (hs-cTnT) below the 99th centile at presentation to the emergency department (ED). DESIGN: Prospective, non-randomised, individual blinded diagnostic accuracy study. SETTING: Two EDs of a rural region of France. PARTICIPANTS: Patients with chest pain suspected of NSTEMI with onset within the last 12 h were considered for enrolment. INTERVENTIONS: Serial clinical, electrographical and biochemical investigations were performed at admission and after 2, 4, 6 and 12 h. Hs-cTnT was measured using an assay with Dimension VISTA, Siemens. Copeptin was measured by the BRAHMS copeptin-us assay on the KRYPTOR Compact Plus system. The follow-up period was 90 days. PRIMARY AND SECONDARY OUTCOME MEASURES: Copeptin, troponin, myoglobin and creatine kinase values. Clinical and paraclinical events. The final diagnosis was adjudicated blinded to copeptin result. RESULTS: During 12 months, 102 patients were analysed. Final diagnosis was NSTEMI for 7.8% (n=8), unstable angina for 3.9% (n=4), cardiac but non-coronary artery disease for 8.8% (n=9), non-cardiac chest pain for 52% (n=53) and unknown for 27.5% (n=28). There was no statistical difference for copeptin values between patients with NSTEMI and others (respectively 5.5 pmol/L IQR (3.1–7.9) and 6.5 pmol/L IQR (3.9–12.1), p=0.49). Only one patient with NSTEMI had a copeptin value above the cut-off of 95th centile at admission. CONCLUSIONS: In this study, copeptin does not add a diagnostic value at admission to ED for patients with suspected acute coronary syndrome without ST-segment elevation and with hs-cTnT below the 99th centile. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov identifier: NCT01334645.